Paysign’s pharmaceutical patient affordability business nearly doubled during the second quarter of 2026, with pharma revenue increasing 88.9% to $14.65 million as the fintech healthcare company rapidly expanded the number of patient support programs operating on its platform.
Paysign added 51 net patient affordability programs over the past 12 months and exited Q2 with 148 active programs. The company expects that figure to reach between 165 and 170 active programs by the end of Q3, implying continued rapid program launches during the current quarter.
Processed pharmaceutical claims increased approximately 54% year-over-year. The growing program base also generated higher monthly management fees, setup fees, claim-processing fees and other billable services, including dynamic business rules and customer service contact-center support.
The shift toward pharmaceutical revenue is improving Paysign’s economics. Total Q2 revenue increased 48.1% to $28.25 million, while gross margin expanded to 63.3% from 61.6%. Paysign said the higher gross margin reflected the greater mix of pharma revenue.
Operating leverage was substantially stronger than top-line growth. Adjusted EBITDA surged 113% to $9.61 million from $4.51 million. GAAP net income increased 386.9% to $6.76 million from $1.39 million.
Reported operating margin expanded to 24.8% from 7.5%. Excluding a one-time $990,000 non-cash fair-value adjustment associated with contingent consideration from the Gamma acquisition, adjusted operating margin was 21.3%.
Paysign’s plasma business also remained resilient despite operating across fewer customer locations. Plasma revenue increased 21.4% to $13.04 million even as the number of plasma centers declined by 46 to 561. Average monthly revenue per center increased to $7,699 from $7,098 as utilization at existing centers improved.
The company raised full-year 2026 revenue guidance to $114 million to $117 million and Adjusted EBITDA guidance to $35 million to $38 million. Paysign ended Q2 with $27.37 million of unrestricted cash and no bank debt.
KEY QUOTES:
“Strong growth in our patient affordability business, steady performance in plasma donor compensation, and disciplined execution across the company drove meaningful operating leverage and profitability, reinforcing the multiyear strategy we have been building.”
“With momentum across the business and a robust pipeline of opportunities, we intend to remain focused on sustainable growth, continued margin expansion, and creating long-term value for shareholders.”
Mark Newcomer, President And Chief Executive Officer Of Paysign
“Our first two quarters of 2026 make two things clear: our patient affordability solutions continue to resonate with pharmaceutical companies, and recent trends in our plasma business indicate improvement from the high inventory levels that weighed on results throughout 2025.”
“Revenue, operating margin and net income all finished above the high end of our guidance, and the strength we’ve seen through the first half of the year, combined with the visibility into additional program launches and seasonal trends, supports our increased full-year outlook.”
Jeff Baker, Chief Financial Officer Of Paysign
